Durand CM, et al. - Researchers herein attempted to investigate the tolerability and feasibility of using direct-acting antivirals (DAAs) as prophylaxis before and after kidney transplantation from hepatitis C virus (HCV)-infected donors to non–HCV-infected recipients (HCV D⁺/R^- transplantation). Findings illustrated the safety of pre- and posttransplantation HCV treatment. This approach also prevented chronic HCV infection in HCV D⁺/R^- kidney transplant recipients. It was determined that this strategy could significantly expand organ options and reduce mortality for kidney transplant candidates without HCV infection.